Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42517   clinical trials with a EudraCT protocol, of which   7000   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Immunization of immunosuppressed patients – Knowledge, practices and serological response

    Summary
    EudraCT number
    2016-004123-23
    Trial protocol
    DK  
    Global end of trial date
    19 Mar 2021

    Results information
    Results version number
    v1(current)
    This version publication date
    24 Jun 2022
    First version publication date
    24 Jun 2022
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    Immunovax_Renal
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Department of Infectious Diseases, Odense University Hospital, Odense, Denmark
    Sponsor organisation address
    J. B. Winsløws Vej 4, Odense C, Denmark, 5000
    Public contact
    Lykke Larsen, Department of Infectious Diseases, Odense University Hospital, 45 65412651, llarsen@dadlnet.dk
    Scientific contact
    Lykke Larsen, Department of Infectious Diseases, Odense University Hospital, 26672029 65412651, llarsen@dadlnet.dk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    13 Dec 2021
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    19 Mar 2021
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    A direct head to head comparison of the specific pneumococcal antibody level pre and post vaccination in the different study groups, for Prenevar 13 and Pneumovax, independently of the immunomodulatory therapy.
    Protection of trial subjects
    No measures were done or needed
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Jun 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Denmark: 139
    Worldwide total number of subjects
    139
    EEA total number of subjects
    139
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    119
    From 65 to 84 years
    20
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Mulige deltagere udfyldte frivilligt spørgeskema og hvis de ønskede deltagelse i lægemiddelstudie blev de inviteret til samtale

    Pre-assignment
    Screening details
    lægelig vurdering og spørgeskema

    Pre-assignment period milestones
    Number of subjects started
    139
    Intermediate milestone: Number of subjects
    vaccinated PCV13: 139
    Number of subjects completed
    139

    Period 1
    Period 1 title
    Overall period
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Recipient- Double dosage
    Arm description
    recieved 1 ml PCV13 and 1 ml PPV23
    Arm type
    Experimental

    Investigational medicinal product name
    13-valent pneumococcal conjugate vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 ml im

    Investigational medicinal product name
    23-valent pneumococcal vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 ml im

    Arm title
    Recipient- Single dosage
    Arm description
    recieved 0.5 ml PCV13 + 0.5 ml PPV23
    Arm type
    Active comparator

    Investigational medicinal product name
    13-valent pneumococcal conjugate vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 ml im

    Investigational medicinal product name
    23-valent pneumococcal vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 ml im

    Arm title
    candidate-double dosage
    Arm description
    recieved 1 ml PCV13 and 1 ml PPV23
    Arm type
    Experimental

    Investigational medicinal product name
    13-valent pneumococcal conjugate vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 ml im

    Investigational medicinal product name
    23-valent pneumococcal vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    1 ml im

    Arm title
    candidate- single dosage
    Arm description
    recieved 0,5 ml PCV13 and 0,5 ml PPV23
    Arm type
    Active comparator

    Investigational medicinal product name
    13-valent pneumococcal conjugate vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    0.5 ml im

    Investigational medicinal product name
    23-valent pneumococcal vaccine
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Injection
    Routes of administration
    Intramuscular use
    Dosage and administration details
    0.5 ml im

    Number of subjects in period 1
    Recipient- Double dosage Recipient- Single dosage candidate-double dosage candidate- single dosage
    Started
    35
    39
    33
    32
    Completed
    35
    37
    32
    31
    Not completed
    0
    2
    1
    1
         Adverse event, serious fatal
    -
    1
    1
    -
         Consent withdrawn by subject
    -
    1
    -
    1

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall period
    Reporting group description
    -

    Reporting group values
    Overall period Total
    Number of subjects
    139 139
    Age categorical
    Units: Subjects
        In utero
    0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days-23 months)
    0 0
        Children (2-11 years)
    0 0
        Adolescents (12-17 years)
    0 0
        Adults (18-64 years)
    119 119
        From 65-84 years
    20 20
        85 years and over
    0 0
    Age continuous
    Units: years
        median (inter-quartile range (Q1-Q3))
    52 (41 to 61) -
    Gender categorical
    Units: Subjects
        Female
    43 43
        Male
    96 96

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Recipient- Double dosage
    Reporting group description
    recieved 1 ml PCV13 and 1 ml PPV23

    Reporting group title
    Recipient- Single dosage
    Reporting group description
    recieved 0.5 ml PCV13 + 0.5 ml PPV23

    Reporting group title
    candidate-double dosage
    Reporting group description
    recieved 1 ml PCV13 and 1 ml PPV23

    Reporting group title
    candidate- single dosage
    Reporting group description
    recieved 0,5 ml PCV13 and 0,5 ml PPV23

    Primary: protective response

    Close Top of page
    End point title
    protective response
    End point description
    End point type
    Primary
    End point timeframe
    5 weeks after PPV23
    End point values
    Recipient- Double dosage Recipient- Single dosage candidate-double dosage candidate- single dosage
    Number of subjects analysed
    35
    39
    33
    32
    Units: 0,1
    9
    13
    20
    11
    Statistical analysis title
    protective response
    Statistical analysis description
    hvor mange har en average pneumococcal AB GMC over 1 mg/L
    Comparison groups
    Recipient- Double dosage v Recipient- Single dosage
    Number of subjects included in analysis
    74
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    > 0.05
    Method
    Chi-squared
    Confidence interval
    Statistical analysis title
    protective response
    Statistical analysis description
    forskel i antal peroner med average pneumococcal AB GMC > 1 mg /L
    Comparison groups
    candidate-double dosage v candidate- single dosage
    Number of subjects included in analysis
    65
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    < 0.05
    Method
    Chi-squared
    Confidence interval

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    5 weeks after PPV23
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    none
    Dictionary version
    1
    Reporting groups
    Reporting group title
    overall
    Reporting group description
    -

    Serious adverse events
    overall
    Total subjects affected by serious adverse events
         subjects affected / exposed
    43 / 139 (30.94%)
         number of deaths (all causes)
    4
         number of deaths resulting from adverse events
    2
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Adverse event
         subjects affected / exposed
    1 / 139 (0.72%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Adverse event
         subjects affected / exposed
    10 / 139 (7.19%)
         occurrences causally related to treatment / all
    0 / 12
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    5 / 139 (3.60%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Immune system disorders
    Adverse event
         subjects affected / exposed
    5 / 139 (3.60%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Nervous system disorders
    Adverse event
         subjects affected / exposed
    2 / 139 (1.44%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Adverse event
    alternative assessment type: Non-systematic
         subjects affected / exposed
    4 / 139 (2.88%)
         occurrences causally related to treatment / all
    0 / 4
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Adverse event
         subjects affected / exposed
    1 / 139 (0.72%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Adverse event
         subjects affected / exposed
    16 / 139 (11.51%)
         occurrences causally related to treatment / all
    0 / 24
         deaths causally related to treatment / all
    0 / 2
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    overall
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    62 / 139 (44.60%)
    General disorders and administration site conditions
    Adverse event following immunisation
         subjects affected / exposed
    62 / 139 (44.60%)
         occurrences all number
    131

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    We were not able to enroll 200 as planned
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA